Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 64

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 64
---
 interests of APx and its shareholders and what may be best for a director’s personal interests when determining to recommend that shareholders vote for the proposals. These conflicts of interest include, among other things, that if we do not consummate an initial business combination by the Extended Date, we may be forced to liquidate, and the 4,312,500 Founder Shares and 8,950,000 Private placement Warrants owned by our Initial Shareholders, would be worthless. See the sections entitled “ Summary of the Proxy Statement / Prospectus — Interests of Certain Persons in the Business Combination” and “ Security Ownership of Certain Beneficial Owners and Management” for more information. Q:May our Sponsor and the other initial shareholders purchase Public Shares or warrants prior to the Special Meeting? A:At any time prior to the Special Meeting, during a period when they are not then aware of any material non -publicinformation regarding APx or our securities, Templar LLC (the “Sponsor”) and APx Cap Sponsor Group I, LLC (the “Initial Sponsor” and, collectively with the Sponsor, the “Initial Shareholders”), the Company and/or their respective affiliates may purchase shares and/or warrants from investors, or they may enter into transactions with such investors and others to provide them with incentives to acquire ordinary shares or vote their shares in favor of the Business Combination Proposal and the other proposals to be presented at the Special Meeting. The purpose of such share purchases and other transactions would be to increase the likelihood that the proposals presented to shareholders for approval at the Special Meeting are approved or to provide additional equity financing. Any such share purchases and other transactions may thereby increase the likelihood of obtaining shareholder approval of the Business Combination. This may result in the completion of the Business Combination that may not otherwise have been possible. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options. Entering into any such incentive arrangements may have a depressive effect on ordinary shares. For example, as a result of these arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he owns, either prior to or immediately after the Special Meeting. If such transactions are effected, the consequence could be to cause the Business Combination to be approved in circumstances where such approval could not otherwise be obtained. Purch